Valorisation

Brevets

1 – Method for detecting the differential expression of a set of molecular markers associated with Parkinson’s disease. The subject matter of the present invention is a method for detecting the differential expression of a set of molecular markers which is associated with the presence of or with the risk of developing Parkinson’s disease, and in particular a sporadic form of this disease. The subject matter of the invention is also a kit or pack for implementing this method.

WO/2010/026335 -METHOD FOR DETECTING THE DIFFERENTIAL EXPRESSION OF A SET OF MOLECULAR MARKERS ASSOCIATED WITH PARKINSON’S DISEASE EPCT/FR2009/051643

2 – This invention concerns a method of predicting an increased risk of a human subject of developing Alzheimer’s disease comprising assaying for a mutation within the ADN sequence of the CP2/LSF/LBP-1 gene including the region controlling the expression of said gene.

WO/2001/048240 -IMPLICATION OF A KNOWN GENE NAMED CP2/LSF-LBP-1 IN ALZHEIMER’S DESEASE PCT/EP2000/013408I

3 – The invention concerns a method for the relative quantization of a first allele, called allele 1, with respect to a second allele, called allele 2, comprising in particular the following steps: a) amplifying the DNA by PCR; b) digesting the amplified DNA by at least one restriction enzyme, for differentiating the alleles; c) separating the DNA fragments; d) evaluating the amount of resulting fragments by means of a marker emitting a signal capable of detection; e) determining the initial percentage in the different alleles, using formula (I).

WO/1999/001575 -METHOD FOR SEMIQUANTIZATION OF ALLELES PCT/FR1998/001413

4 – The invention concerns a method for diagnosing Alzheimer disease, consisting in demonstrating one or several mutations in the genomic DNA region regulating the expression of the apolipoprotein E gene, inducing a modification of the apolipoprotein E gene, with respect to a control population or a modification of the expression relative to the alleles of the apolipoprotein E gene.

WO/1999/001574 -METHOD FOR DIAGNOSING ALZHEIMER DISEASE PCT/FR1998/001394

5 – Combined use of at least two genetic markers selected from apolipoprotein E, D19S178 and apolipoprotein CII, for the diagnosis of Alzheimer’s disease, especially apolipoprotein ε4, long apolipoprotein CII (30+/-3 repeat patterns (CA) and short D19S178 (less than 167+/-4 nucleotides) alleles. The invention also concerns a method for the diagnosis of Alzheimer’s disease and a kit for carrying out said method.

WO/1995/024504 -COMBINED USE OF GENETIC MARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE, DIAGNOSTIC KIT AND METHOD PCT/FR1995/000259

6 – Model systems of Alzheimer’s disease comprise a DNA sequence encoding an amyloid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding to amino acid residue position 717 of APP770. Methods of determining genetic predisposition to Alzheimer’s disease are also disclosed.

WO/1992/013069 -TEST AND MODEL FOR ALZHEIMER’S DISEASE 06.08.1992 C07K 14/47 PCT/GB1992/000123

Prix

MC Chartier-Harlin :

-Aimée et Raymond Mandé2005 : maladie de Parkinson

http://www.academie-medecine.fr/detailPrix.cfm?idRub=63&idLigne=154

-FRM régionale 2010 : Mitochondrie et marqueurs de la maladie de Parkinson

Christel Vanbesien-Mailliot :

-Programme Aasgard 2011 (Norvège)